Evidence map›Paper›PMID 35273565›Full record

ReviewFrontiers in endocrinology2022

Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan.

Marek Bolanowski, Zaina Adnan, Mirjana Doknic, Mykola Guk, Václav Hána, Irena Ilovayskaya, Darko Kastelan, Tomaz Kocjan, Martin Kužma, Akmaral Nurbekova and 7 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. What is the future of acromegaly therapy?The Journal of clinical endocrinology and metabolism · 2026
    Review
  2. Article
  3. Integrated Approach to Patient Engagement in Obtaining Dental Services.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024
    Article
  4. Observational
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 16 institutions in 15 countries.

Marek BolanowskiDepartment of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland.
Zaina AdnanDivision of Endocrinology and Metabolism, Bar Ilan Faculty of Medicine, Clalit Medical Health Care Services, Safed, Israel.
Mirjana DoknicNeuroendocrinology Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Medical Faculty University of Belgrade, Belgrade, Serbia.
Mykola GukDepartment of Transsphenoidal Surgery, Romodanov Neurosurgery Institute, Kyiv, Ukraine.
Václav HánaThird Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia.
Irena IlovayskayaNeuroendocrine Unit, Endocrinology Department, Moscow Regional Research and Clinical Institute, Moscow, Russia.
Darko KastelanDepartment of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia.
Tomaz KocjanDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Martin KužmaComenius University Faculty of Medicine, 5th Department of Internal Medicine, University Hospital Bratislava, Bratislava, Slovakia.
Akmaral NurbekovaKazakh National Medical University, Almaty, Kazakhstan.
Catalina PoianaDepartment of Endocrinology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Nikolette SzücsDepartment of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Silvia VandevaDepartment of Endocrinology, Specialized Hospital for Active Treatment of Endocrinology, Medical University, Sofia, Bulgaria.
Roy GomezGlobal Medical Affairs, Pfizer Rare Disease, Brussels, Belgium.
Sorin PaidacMedical Affairs, Pfizer Rare Disease, Bucharest, Romania.
Damien SimoneauCentral and Eastern Europe Medical Affairs, Pfizer Rare Disease, Paris, France.
Ilan ShimonRabin Medical Center, Petah-Tikva, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Carol Davila University of Medicine and Pharmacy · ROCharles University · CZClalit Health Services · ILKazakh National Medical University · KZLjubljana University Medical Centre · SIMoscow Regional Research Institute of Obstetrics and Gynecology · RUPfizer (Belgium) · BEPfizer (France) · FRRomodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine · UASemmelweis University · HUTel Aviv University · ILUniversity Hospital Bratislava · SKUniversity Hospital Centre Zagreb · HRUniversity of Belgrade · RSUniversity Specialized Hospital for Active Treatment of Endocrinology · BGWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acromegaly is a rare condition typically caused by benign pituitary adenomas, resulting in excessive production of growth hormone. Clinical manifestations of acromegaly are diverse, varying from the overgrowth of body tissue to cardiovascular, metabolic, and osteoarticular disorders. Symptoms may emerge slowly, overlapping with other diseases and often involve many different healthcare specialists. In the last decade, efforts to provide an accurate and timely diagnosis of acromegaly have improved disease management and clinical experience. Despite this progress, marked differences in the diagnosis, treatment, and management of acromegaly exist from country-to-country. To address these inconsistencies in the region comprising Central and Eastern Europe, Israel, and Kazakhstan, a panel of acromegaly experts from 13 of these countries was convened. Acromegaly experts from each country provided available information on the approaches from their country, including regional treatment centers and multidisciplinary teams, treatment access, reimbursement and availability, and physician education, disease awareness, and patient advocacy. Across several areas of acromegaly management, divergent approaches were identified and discussed, including the provision of multidisciplinary care, approved and available treatments, and disease awareness programs. These were recognized as areas of potential improvement in the management of acromegaly, in addition to participation in national and regional acromegaly registries. Further experience exchange will facilitate the identification of specific strategies that can be adapted in each country, and widespread participation in acromegaly registries will enable their evaluation. It is anticipated that this approach will support the optimization of acromegaly patient care across this region.

Indexed as

AcromegalyEurope, EasternGrowth HormoneHumansIsraelKazakhstanGrowth HormoneacromegalyendocrinologyIGF-Imultidisciplinary carereferral pathway

Identifiers

PMID35273565
PMCPMC8902495
OpenAlexW4213354377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.